<DOC>
	<DOCNO>NCT00518726</DOCNO>
	<brief_summary>To evaluate antibody response influenza vaccine antigen administer single dose subject age &gt; 18 year</brief_summary>
	<brief_title>Safety Immunogenicity Commercially Available Influenza Vaccine ( Formulation 2007/2008 ) When Administered NON Elderly AND Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>&gt; 18 year age older serious disease cancer , autoimmune disease , advance arteriosclerotic disease complicate diabetes mellitus , chronic obstructive pulmonary disease ( COPD ) require oxygen therapy , acute progressive hepatic disease , acute progressive renal disease , congestive heart failure bleed diathesis condition associate prolonged bleeding time hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin polymyxin component vaccine history neurological symptom sign , anaphylactic shock follow administration vaccine know suspect ( high risk develop ) impairment/alteration immune function within past 7 day , acute disease infection require systemic antibiotic antiviral therapy fever within past 3 days.No woman breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Adjuvanted Influenza Vaccine</keyword>
</DOC>